TuHURA Biosciences Price to Free Cash Flow Ratio 2010-2024 | HURA

TuHURA Biosciences price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as

TuHURA Biosciences Price to Free Cash Flow Ratio 2010-2024 | HURA

TuHURA Biosciences price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.8B
Vertex Pharmaceuticals (VRTX)$122.6B
Gilead Sciences (GILD)$109.8B
Bristol Myers Squibb (BMY)$107B
Regeneron Pharmaceuticals (REGN)$106.1B
CSL (CSLLY)$96.1B
GSK (GSK)$78.8B
Alnylam Pharmaceuticals (ALNY)$38.1B
Argenex SE (ARGX)$34B
Biogen (BIIB)$27.1B
BioNTech SE (BNTX)$26.4B
Illumina (ILMN)$22.9B
BeiGene (BGNE)$21.5B
Moderna (MRNA)$20.5B
Genmab (GMAB)$15.1B
BioMarin Pharmaceutical (BMRN)$13.4B
Exact Sciences (EXAS)$13B
Insmed (INSM)$12.7B
Incyte (INCY)$12.6B
Vaxcyte (PCVX)$12.6B
Sarepta Therapeutics (SRPT)$12.2B
Bio-Techne Corp (TECH)$11.1B
QIAGEN (QGEN)$9.6B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.7B
Exelixis (EXEL)$8.2B
Legend Biotech (LEGN)$8.2B
Intra-Cellular Therapies (ITCI)$8.1B
Repligen (RGEN)$8.1B
Revolution Medicines (RVMD)$7.9B